Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

ANI Pharmaceuticals, Inc. (ANIP) had Revenue of $197.12M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$197.12M
Net Income	$15.28M
Cost of Goods Sold	$73.04M
Gross Profit	$124.08M
Operating Expenses	$170.93M
Operating Income	$26.19M
Non-Operating Income/Expense	$-6.21M
Pre-Tax Income	$19.99M
Normalized Pre-Tax Income	$19.99M
Income after Taxes	$15.68M
Income from Continuous Operations	$15.68M
Consolidated Net Income/Loss	$15.68M
Normalized Income after Taxes	$15.68M
EBIT	$26.19M
EBITDA	$49.09M
Weighted-Average Shares Outstanding (Basic)	19.61M
Weighted-Average Shares Outstanding (Diluted)	20.05M
Earnings per Share (EPS) (Basic)	$0.70
Earnings per Share (EPS) (Diluted)	$0.69
Balance Sheet Financials
Current Assets	$536.29M
Property, Plant, and Equipment	$58.18M
Long-Term Assets	$756.14M
Total Assets	$1.29B
Current Liabilities	$201.81M
Long-Term Debt	$611.63M
Long-Term Liabilities	$647.14M
Total Liabilities	$848.96M
Common Equity	$418.62M
Tangible Shareholders Equity	$-155.69M
Shareholders Equity	$443.47M
Common Shares Outstanding	21.67M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$34.99M
Cash Flow from Investing Activities	$-19.85M
Cash Flow from Financial Activities	$-9.91M
Beginning Cash	$144.89M
End Cash	$149.84M
Increase/Decrease in Cash	$4.94M
Stock-Based Compensation	$8.87M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	$-0.41M
Fundamental Metrics & Ratios
Current Ratio	2.66
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.58
Debt to Equity Ratio	1.40
Gross Margin	62.95%
Operating Margin	13.29%
EBIT Margin	13.29%
EBITDA Margin	--
Pre-Tax Profit Margin	10.14%
Profit Margin	7.75%
Free Cash Flow	$32.52M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.53
Receiveable Turnover	0.89
Days Sales in Receivables	100.60
Return on Equity	3.75%
Return on Tangible Equity	-10.07%
Return on Assets	1.21%
Return on Investments	1.49%
Book Value Per Share	$20.46
Free Cash Flow per Share	$1.62
Operating Cash Flow per Share	$1.75

Data from Zacks Investment Research, Inc.